Showing 1311-1320 of 2531 results for "".
- FDA Approves Lilly's Taltz for Treatment Of Pediatric Patients with Psoriasishttps://practicaldermatology.com/news/fda-approves-lillys-taltz-for-treatment-of-pediatric-patients-with-psoriasis/2460327/The FDA has approved a supplemental Biologics License Application (sBLA) for Eli Lilly and Company's Taltz (ixekizumab) injection, 80 mg/mL for the treatment of pediatric patients (ages 6 to under 18) with moderate to severe plaque psoriasis who are c
- Study: Mohs Scars from Facial Skin Cancers Longer than Patients Expecthttps://practicaldermatology.com/news/study-mohs-scars-from-facial-skin-cancers-longer-than-patients-expect/2460301/Scars from Mohs micrographic surgery for facial skin cancers may be longer than patients expect, according to new research published in JAMA Network Open. In this cross-sectional study of 1
- First Patient Enrolled in Avita Medical’s Pivotal Study Evaluating Recell System for Soft Tissue Reconstructionhttps://practicaldermatology.com/news/first-patient-enrolled-in-avita-medicals-pivotal-study-evaluating-recell-system-for-soft-tissue-reconstruction/2460294/Avita Medical Limited enrolled the first patient in a study evaluating the Recell System for Soft Tissue Reconstruction at the Arizona Burn Center at Valleywise Medical Health Center in Phoenix, AZ. The prospective multi-center trial of at least 65 patients will compare the clinical per
- Cold Plasma Patch May Make Immunotherapy More Effective for Treating Melanomahttps://practicaldermatology.com/news/cold-plasma-patch-may-make-immunotherapy-more-effective-for-treating-melanoma/2460275/A new medicated patch that can deliver immune checkpoint inhibitors and cold plasma directly to tumors may help boost the immune response and kill cancer cells, according to an interdisciplinary team of researchers at the UCLA Jonsson Comprehensive Cancer Center. The thumb-sized patch h
- Revian Awarded Patent for Biostimulatory Light Combinationshttps://practicaldermatology.com/news/revian-awarded-patent-for-biostimulatory-light-technology/2460249/Revian Inc. has received from the United States Patent and Trademark Office (USPTO) U.S. Patent No. 10,265,258—the seminal patent on the use of proprietary color combinations of light to regenerate living tissue in the body. The claims in this issued patent cover the u
- Norfolk Dermatologist Recognized for Increasing Accessibility for Patientshttps://practicaldermatology.com/news/norfolk-dermatologist-recognized-for-increasing-accessibility-for-patients/2460227/Dermatologist Abby Van Voorhees, MD, FAAD, is an American Academy of Dermatology Patient Care Hero for her leadership at the Rapid Access Clinic at the Eastern Virginia Medical School Dermatology Practice in Norfolk, Va. The Eastern Virginia Medical School Dermatology practice allo
- Cassiopea Enrolls First Patient in Phase II Trial of Clascoterone Solution for the Treatment of Androgenetic Alopecia in Femaleshttps://practicaldermatology.com/news/cassiopea-enrolls-first-patient-in-phase-ii-trial-of-clascoterone-solution-for-the-treatment-of-androgenetic-alopecia-in-females/2460215/After receiving approval from the German Authority BfArM and the coordinating ethical committee, Cassiopea SpA is now enrolling the first patient in a Phase II trial investigating clascoterone solution for the treatment of androgenetic alopecia (AGA) in fema
- ASDSA Honors 2019 Patient Safety Heroeshttps://practicaldermatology.com/news/asdsa-honors-2019-patient-safety-heroes/2460203/The American Society for Dermatologic Surgery Association (ASDSA) honored the recipients of its annual Patient Safety Hero awards at the recent ASDS Annual Meeting in Chicago, Illinois. The ASDSA State Legislative Patient Safety Hero Award is presented to a state legislative member who
- Increased Adherence, Symptom Improvement Seen When Psoriasis Patients Switch to IL-17 Blockershttps://practicaldermatology.com/news/increased-adherence-symptom-improvement-seen-when-psoriasis-patients-switch-to-il-17-blockers/2460147/New data points to increased adherence and improvement in symptoms for psoriasis patients who switch to interleukin-17 inhibitors. The study, which was conducted with Walgreens, a parent company of AllianceRx Walgreens Prime, was presented at the National Association of Specialty Pharma
- Melanoma Breakthrough: Researchers Discover Why Some Patients Respond to Immunotherapyhttps://practicaldermatology.com/news/melanoma-breakthrough-researchers-discover-why-some-patients-respond-to-immunotherapy-yet-others-dont/2460143/Israeli researchers now know why 60 percent of patients with metastatic melanoma do not respond to immunotherapy. After examining tumors of 116 patients using proteomics, the researchers found the non-responding patients tended to have lower fatty acid metabolism, meaning that their enz